Cargando…
Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis
BACKGROUND: Ocrelizumab was found to decrease brain atrophy rate in primary progressive multiple sclerosis (PPMS), but no data are currently available on the effect of ocrelizumab on retinal layer thicknesses in the PPMS population. OBJECTIVE: To assess retinal layer changes in ocrelizumab-treated P...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467948/ https://www.ncbi.nlm.nih.gov/pubmed/35648233 http://dx.doi.org/10.1007/s00415-022-11183-y |
_version_ | 1784788305139728384 |
---|---|
author | Miscioscia, Alessandro Puthenparampil, Marco Miante, Silvia Pengo, Marta Rinaldi, Francesca Perini, Paola Gallo, Paolo |
author_facet | Miscioscia, Alessandro Puthenparampil, Marco Miante, Silvia Pengo, Marta Rinaldi, Francesca Perini, Paola Gallo, Paolo |
author_sort | Miscioscia, Alessandro |
collection | PubMed |
description | BACKGROUND: Ocrelizumab was found to decrease brain atrophy rate in primary progressive multiple sclerosis (PPMS), but no data are currently available on the effect of ocrelizumab on retinal layer thicknesses in the PPMS population. OBJECTIVE: To assess retinal layer changes in ocrelizumab-treated PPMS and test their possible application as biomarkers of therapy response. METHODS: 36 PPMS patients, treated with ocrelizumab for at least 6 months, and 39 sex- and age-matched healthy controls (HC) were included in a blind, longitudinal study. Spectrum-domain optical coherence tomography (SD-OCT) was performed at study entry (T0) and after 6 (T6) and 12 months (T12). At month 24 (T24), patients were divided into responders (no evidence of 1-year confirmed disability progression, 1y-CDP) and non-responders (evidence of 1y-CDP). RESULTS: At T24, 23/36 (64%) patients were considered responders and 13/36 (36%) non-responders. At T0, peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell–inner plexiform layer (GCIPL) and inner retinal layer (IRL) volume were significantly lower in PPMS compared to HC (p = 0.001 for all comparisons). At T6 and T12, non-responders significantly differed in the inner nuclear layer (INL) thinning rate compared to responders (p = 0.005 at both time-points). CONCLUSIONS: Ocrelizumab significantly slows down INL thinning rate in PPMS responders. The longitudinal analysis of retina layer changes by means of OCT may be a promising prognostic test, and merits further investigations. |
format | Online Article Text |
id | pubmed-9467948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94679482022-09-14 Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis Miscioscia, Alessandro Puthenparampil, Marco Miante, Silvia Pengo, Marta Rinaldi, Francesca Perini, Paola Gallo, Paolo J Neurol Original Communication BACKGROUND: Ocrelizumab was found to decrease brain atrophy rate in primary progressive multiple sclerosis (PPMS), but no data are currently available on the effect of ocrelizumab on retinal layer thicknesses in the PPMS population. OBJECTIVE: To assess retinal layer changes in ocrelizumab-treated PPMS and test their possible application as biomarkers of therapy response. METHODS: 36 PPMS patients, treated with ocrelizumab for at least 6 months, and 39 sex- and age-matched healthy controls (HC) were included in a blind, longitudinal study. Spectrum-domain optical coherence tomography (SD-OCT) was performed at study entry (T0) and after 6 (T6) and 12 months (T12). At month 24 (T24), patients were divided into responders (no evidence of 1-year confirmed disability progression, 1y-CDP) and non-responders (evidence of 1y-CDP). RESULTS: At T24, 23/36 (64%) patients were considered responders and 13/36 (36%) non-responders. At T0, peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell–inner plexiform layer (GCIPL) and inner retinal layer (IRL) volume were significantly lower in PPMS compared to HC (p = 0.001 for all comparisons). At T6 and T12, non-responders significantly differed in the inner nuclear layer (INL) thinning rate compared to responders (p = 0.005 at both time-points). CONCLUSIONS: Ocrelizumab significantly slows down INL thinning rate in PPMS responders. The longitudinal analysis of retina layer changes by means of OCT may be a promising prognostic test, and merits further investigations. Springer Berlin Heidelberg 2022-06-01 2022 /pmc/articles/PMC9467948/ /pubmed/35648233 http://dx.doi.org/10.1007/s00415-022-11183-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Miscioscia, Alessandro Puthenparampil, Marco Miante, Silvia Pengo, Marta Rinaldi, Francesca Perini, Paola Gallo, Paolo Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis |
title | Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis |
title_full | Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis |
title_fullStr | Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis |
title_full_unstemmed | Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis |
title_short | Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis |
title_sort | retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467948/ https://www.ncbi.nlm.nih.gov/pubmed/35648233 http://dx.doi.org/10.1007/s00415-022-11183-y |
work_keys_str_mv | AT misciosciaalessandro retinalinnernuclearlayerthinningisdecreasedandassociateswiththeclinicaloutcomeinocrelizumabtreatedprimaryprogressivemultiplesclerosis AT puthenparampilmarco retinalinnernuclearlayerthinningisdecreasedandassociateswiththeclinicaloutcomeinocrelizumabtreatedprimaryprogressivemultiplesclerosis AT miantesilvia retinalinnernuclearlayerthinningisdecreasedandassociateswiththeclinicaloutcomeinocrelizumabtreatedprimaryprogressivemultiplesclerosis AT pengomarta retinalinnernuclearlayerthinningisdecreasedandassociateswiththeclinicaloutcomeinocrelizumabtreatedprimaryprogressivemultiplesclerosis AT rinaldifrancesca retinalinnernuclearlayerthinningisdecreasedandassociateswiththeclinicaloutcomeinocrelizumabtreatedprimaryprogressivemultiplesclerosis AT perinipaola retinalinnernuclearlayerthinningisdecreasedandassociateswiththeclinicaloutcomeinocrelizumabtreatedprimaryprogressivemultiplesclerosis AT gallopaolo retinalinnernuclearlayerthinningisdecreasedandassociateswiththeclinicaloutcomeinocrelizumabtreatedprimaryprogressivemultiplesclerosis |